Ann: Final Antibody Selection Complete, page-31

There is still a while till this stock will truly get moving IMO, they need the clinical trials of the screening to be completed before any interest will come into it like BD1 recently. Huge potential especially if these clinical trials prove the test is just as good or better and for a fraction of the price, potential market size is just behind that of breast cancer and should hopefully justify a great rerate like that of BD1,

Seems they are aiming for 2020 commercialisation, which is not too long in the grand scheme of things and would thus imply clinical trials should take less than 12-14months from now